Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Non-Current Debt (2016 - 2025)

Pediatrix Medical (MD) has disclosed Non-Current Debt for 17 consecutive years, with $570.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 4.45% to $570.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $570.5 million, a 4.45% decrease, with the full-year FY2025 number at $570.5 million, down 4.45% from a year prior.
  • Non-Current Debt was $570.5 million for Q4 2025 at Pediatrix Medical, down from $577.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.0 billion in Q3 2021 to a low of $41.0 million in Q2 2023.
  • A 5-year average of $608.5 million and a median of $613.0 million in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: tumbled 93.59% in 2023, then surged 1394.24% in 2024.
  • Pediatrix Medical's Non-Current Debt stood at $1.0 billion in 2021, then crashed by 36.9% to $632.4 million in 2022, then decreased by 2.21% to $618.4 million in 2023, then decreased by 3.44% to $597.1 million in 2024, then decreased by 4.45% to $570.5 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Non-Current Debt are $570.5 million (Q4 2025), $577.2 million (Q3 2025), and $583.9 million (Q2 2025).